FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
What happened
FDA inspected the facility from December 13 to 20, 2024, and observed live rodents and birds, rodent and bird droppings, mold, and insects in areas storing finished drugs and packaging. The firm had not responded to the inspection observations (Form FDA 483) despite two FDA inquiries; after FDA detained a March 19, 2025 shipment, the firm requested a 90-day extension. FDA also cited CGMP (current good manufacturing practice) violations in component identity testing and quality unit oversight, placed the firm on Import Alert 66-40, and a distributor recalled products.
What FDA found
FDA found live rodents and birds, droppings, mold, and insects in areas storing finished drug products and packaging.
FD&C Act section 501(a)(2)(A)The firm did not perform identity testing on incoming components, did not verify supplier certificates of analysis, and lacked quarantine or approval controls.
21 CFR 211.84(d)(1) and (d)(2)The quality unit, which is responsible for quality oversight, failed to ensure adequate written procedures for complaints, deviations, investigations, cleaning, maintenance, training, and labeling.
21 CFR 211.22(d)The firm lacked adequate validation of production and process controls, including qualification of manufacturing equipment.
21 CFR 211.100(a)The firm lacked adequate batch production and control records documenting each significant manufacturing step.
21 CFR 211.188(b)The firm lacked adequate written procedures for test methods and sampling plans and adequate cleaning procedures and cleaning validation.
21 CFR 211.160(b), 211.67(a), 211.67(b)
What FDA wants
FDA tells Healwell to correct the violations promptly and respond in writing within 15 working days with plans to decontaminate the facility, maintain pest-free buildings, fix component testing and quality unit oversight, and assess risks to distributed lots.
Who should pay attention
- brands or distributors buying homeopathic or OTC drugs from this contract manufacturer
- U.S. importers of Indian drug products
- quality teams responsible for supplier qualification and pest control at storage sites
This is a summary. Read the original letter on fda.gov.